AstraZeneca, Icosavax withdraw, resubmit US pre-merger forms, triggering new waiting period until Feb. 16
Global pharmaceutical company AstraZeneca and its acquisition target, research-stage vaccine developer Icosavax, announced today in a securities filing that they've pulled and refiled US antitrust paperwork for their $1.1 billion transaction.Global...To view the full article, register now.
Already a subscriber? Click here to view full article